Table 2.
HPV prevalence measured by LA and Q-PCR in cervical disease categories
| Disease category | Total no. of subjects | Mean age (yrs [range]) | No. of subjects with multiple infectionsa | No. of infections by HPV type and assay method |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HPV16 |
HPV18 |
HPV31 |
HPV33 |
HPV52 |
|||||||||
| LA | Q-PCR | LA | Q-PCR | LA | Q-PCR | LA | Q-PCR | LA | Q-PCR | ||||
| <CIN2 and normal cytology | 13 | 25 (19-37) | 11 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 |
| <CIN2 and ASCUS or LSIL | 19 | 27 (19-41) | 14 | 9 | 9 | 3 | 3 | 5 | 5 | 2 | 2 | 4 | 4 |
| <CIN3 and HSIL | 42 | 28 (18-64) | 31 | 21 | 20 | 12 | 12 | 5 | 5 | 8 | 7 | 9 | 9 |
| CIN3 | 17 | 29 (19-52) | 13 | 8 | 8 | 5 | 5 | 4 | 4 | 5 | 5 | 1 | 1 |
| Cancer | 13 | 49 (38-69) | 5 | 9 | 9 | 3 | 3 | 0 | 0 | 1 | 1 | 1 | 0 |
| Total | 104 | 74 | 51 | 49 | 26 | 26 | 17 | 17 | 18 | 17 | 17 | 16 | |
a
Based on Linear Array (LA) genotyping. Disease categories are nonoverlapping.